0.3601
price up icon4.38%   0.0151
pre-market  Pre-market:  .38   0.0199   +5.53%
loading
Genprex Inc stock is traded at $0.3601, with a volume of 1.81M. It is up +4.38% in the last 24 hours and down -23.55% over the past month. Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
See More
Previous Close:
$0.345
Open:
$0.36
24h Volume:
1.81M
Relative Volume:
2.07
Market Cap:
$3.06M
Revenue:
-
Net Income/Loss:
$-22.71M
P/E Ratio:
-0.0308
EPS:
-11.71
Net Cash Flow:
$-18.24M
1W Performance:
+7.49%
1M Performance:
-23.55%
6M Performance:
-14.26%
1Y Performance:
-91.41%
1-Day Range:
Value
$0.349
$0.40
1-Week Range:
Value
$0.3142
$0.40
52-Week Range:
Value
$0.2806
$4.48

Genprex Inc Stock (GNPX) Company Profile

Name
Name
Genprex Inc
Name
Phone
512-537-7997
Name
Address
1601 TRINITY STREET, BLDG. B, AUSTIN, TX
Name
Employee
25
Name
Twitter
@genprex
Name
Next Earnings Date
2024-11-12
Name
Latest SEC Filings
Name
GNPX's Discussions on Twitter

Compare GNPX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
GNPX
Genprex Inc
0.3601 3.06M 0 -22.71M -18.24M -11.71
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
502.92 129.14B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
680.61 74.41B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
581.21 35.31B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
241.75 31.30B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
254.57 27.35B 3.32B -860.46M -1.04B -8.32

Genprex Inc Stock (GNPX) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-26-21 Initiated National Securities Buy
Apr-29-19 Initiated Noble Capital Markets Outperform

Genprex Inc Stock (GNPX) Latest News

pulisher
Mar 13, 2025

Genprex Inc (GNPX) Is On The Launchpad, Waiting For Long-Term Buyers. - Stocks Register

Mar 13, 2025
pulisher
Mar 04, 2025

Genprex to Participate at BIO Europe Spring 2025 - PR Newswire

Mar 04, 2025
pulisher
Feb 27, 2025

Genprex to Present at the 2020 LD Micro Virtual Conference - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 20, 2025

Genprex Strengthens Diabetes Focus with New License - TipRanks

Feb 20, 2025
pulisher
Feb 19, 2025

Genprex explores non-viral gene therapy for diabetes By Investing.com - Investing.com Nigeria

Feb 19, 2025
pulisher
Feb 19, 2025

Genprex Advances Diabetes Program With Addition Of Research Focused On Non-Viral Delivery System - Marketscreener.com

Feb 19, 2025
pulisher
Feb 19, 2025

Genprex explores non-viral gene therapy for diabetes - Investing.com India

Feb 19, 2025
pulisher
Feb 19, 2025

Can This New Delivery System Transform Diabetes Gene Therapy? Genprex's Latest Breakthrough - StockTitan

Feb 19, 2025
pulisher
Feb 18, 2025

Genprex advances diabetes gene therapy with new license By Investing.com - Investing.com Nigeria

Feb 18, 2025
pulisher
Feb 18, 2025

Genprex Provides Update On Diabetes Gene Therapy Program -February 18, 2025 at 10:03 am EST - Marketscreener.com

Feb 18, 2025
pulisher
Feb 18, 2025

Genprex announces advancement of its diabetes gene therapy program - TipRanks

Feb 18, 2025
pulisher
Feb 18, 2025

Genprex advances diabetes gene therapy with new license - Investing.com India

Feb 18, 2025
pulisher
Feb 18, 2025

Genprex Provides Update on Diabetes Gene Therapy Program - Nasdaq

Feb 18, 2025
pulisher
Feb 14, 2025

Genprex faces Nasdaq delisting over stock price, equity issues - MSN

Feb 14, 2025
pulisher
Feb 14, 2025

Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer - BioSpace

Feb 14, 2025
pulisher
Feb 13, 2025

Genprex's New Study Highlights NPRL2 Gene Therapy's Antitumor Activity In Lung Cancer - Nasdaq

Feb 13, 2025
pulisher
Feb 13, 2025

Understanding GNPX’s financial ratios: A beginner’s guide - US Post News

Feb 13, 2025
pulisher
Feb 12, 2025

Genprex faces Nasdaq delisting over stock price, equity issues By Investing.com - Investing.com Canada

Feb 12, 2025
pulisher
Feb 06, 2025

Contrasting Genprex (NASDAQ:GNPX) & Avadel Pharmaceuticals (NASDAQ:AVDL) - Defense World

Feb 06, 2025
pulisher
Feb 05, 2025

GNPX’s Market Whiplash: -38.94% YTD Decline, -42.28% Plunge in 30 Days - The InvestChronicle

Feb 05, 2025
pulisher
Jan 24, 2025

Genprex Inc (NASDAQ: GNPX): An Enticing Stock To Watch - Stocks Register

Jan 24, 2025
pulisher
Jan 24, 2025

Genprex doses first subject in expansion part of lung cancer gene therapy trial - Clinical Trials Arena

Jan 24, 2025
pulisher
Jan 23, 2025

Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa® Gene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer - PR Newswire

Jan 23, 2025
pulisher
Jan 15, 2025

Genprex, Inc. (NASDAQ: GNPX) Provides Updates on Oncology and Diabetes Programs - Defense World

Jan 15, 2025
pulisher
Jan 14, 2025

Genprex Advances Cancer Trials and Diabetes Therapy - Yahoo Finance

Jan 14, 2025
pulisher
Jan 06, 2025

Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference - BioSpace

Jan 06, 2025
pulisher
Dec 20, 2024

SEC Form 424B5 filed by Genprex Inc. - Quantisnow

Dec 20, 2024
pulisher
Dec 18, 2024

Genprex Completes Phase 1 Dose Escalation of Acclaim-3 Clinical Trial for ES-SCLC PatientsGenprex, Inc. (NASDAQ:GNPX) announced in a press release dated December 16, 2024, the successful completion of the Phase 1 dose escalation segment of the - Defense World

Dec 18, 2024
pulisher
Dec 16, 2024

Genprex advances to phase 2 in lung cancer trial - Investing.com

Dec 16, 2024
pulisher
Dec 16, 2024

Genprex's Reqorsa Advances to Phase 2 After Successful Safety Trial in Lung Cancer Treatment - StockTitan

Dec 16, 2024
pulisher
Dec 16, 2024

Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer - PR Newswire

Dec 16, 2024
pulisher
Dec 10, 2024

Genprex to Present and Participate at Upcoming September Investor and Industry Conferences - The Eastern Progress Online

Dec 10, 2024
pulisher
Dec 07, 2024

Genprex to Participate in 2024 BIO Europe Conference - The Eastern Progress Online

Dec 07, 2024
pulisher
Nov 30, 2024

Genprex Collaborators Present Positive Preclinical Data on the U - GuruFocus.com

Nov 30, 2024
pulisher
Nov 25, 2024

Genprex Collaborators to Present Positive Preclinical Data on th - GuruFocus.com

Nov 25, 2024
pulisher
Nov 21, 2024

Genprex links with University of Michigan on lung cancer treatment - Yahoo Finance

Nov 21, 2024
pulisher
Nov 21, 2024

Genprex secures exclusive gene therapy license for cancer By Investing.com - Investing.com Canada

Nov 21, 2024
pulisher
Nov 20, 2024

Genprex secures exclusive gene therapy license for cancer - Investing.com India

Nov 20, 2024
pulisher
Nov 20, 2024

Genprex Secures Global Patent Rights for Breakthrough Lung Cancer Gene Therapy | GNPX Stock News - StockTitan

Nov 20, 2024

Genprex Inc Stock (GNPX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$75.07
price up icon 1.39%
$305.39
price down icon 0.55%
$19.19
price down icon 3.62%
$32.68
price down icon 0.52%
$97.47
price down icon 2.84%
biotechnology ONC
$254.57
price up icon 1.89%
Cap:     |  Volume (24h):